MISSISSAUGA, ON, June 3, 2020 /CNW/ - Covalon Technologies Ltd.
(the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced
medical technologies company, today announced that the Company has
been granted key antimicrobial patents by the United States Patent
and Trademark Office ("USPTO"), the Canadian Intellectual Property
Office ("CIPO"), and the European Patent Office ("EPO").
Covalon's Antimicrobial Silicone-based Wound Dressing patent has
been granted in the United States
by the USPTO, in Canada by the
CIPO, and in Europe by the EPO.
This antimicrobial patent is integral to the Company's CovaClear®
platform technology and the Company's IV Clear®, MediClear® PreOp,
and SurgiClear® products.
The USPTO also granted the Company a patent for a Method for the
Reduction of Microbial Skin Flora, which protects the Company's
novel product MediClear PreOp. MediClear PreOp is indicated for use
as a pre-operative drape that provides continuous antimicrobial
activity to reduce the risk of contamination of the skin prior to a
surgical procedure.
"This is a major accomplishment to protect the only
dual-antimicrobial silicone adhesive technology on the market,"
said Brian Pedlar, Covalon's Chief
Executive Officer. "We are very pleased to see that the United States, Canadian, and European
patent offices have all recognized Covalon's innovations in
antimicrobial technologies through the granting of these
patents. Protecting patients from infection during hospital
procedures is a significant growth opportunity and these patents
solidify Covalon's advantage in this market."
IV Clear® is the only dual-antimicrobial fully transparent
silicone vascular access dressing on the market. The patented
technology incorporates chlorohexidine and silver into the entire
surface area of the adhesive, ensuring the greatest area of
coverage and protection from bacterial migration by preventing
regrowth of microorganisms most commonly associated with CRBSI's
(catheter-related bloodstream infections) for up to seven
days.
MediClear PreOp® is a novel self-adherent dual-antimicrobial
film indicated for use as a pre-operative drape that kills, on
average, 99.99% of microorganisms in just 30 minutes, while also
physically isolating the site from external contaminants, ensuring
complete site protection leading up to surgery. MediClear PreOp is
designed to be applied by the patient or a clinician prior to a
surgical procedure and removed in the operating room just before
surgery.
SurgiClear® is a post-surgical dressing designed to protect
patients during recovery. This dual-antimicrobial dressing is
applied over a closed surgical wound to provide barrier protection
to external contaminants, full visibility of the healing site, and
full-surface antimicrobial coverage to protect the patient from
bacterial regrowth for up to seven days. The soft silicone
technology conforms extremely well to the contours of the skin,
allowing for better mobility during recovery without sacrificing
antimicrobial protection.
About Covalon
Covalon Technologies Ltd.
researches, develops, and commercializes new healthcare
technologies that help save lives around the world. Covalon's
patented technologies, products, and services address the advanced
healthcare needs of medical device companies, healthcare providers,
and individual consumers. Covalon's technologies are used to
prevent, detect, and manage medical conditions in specialty areas
such as infection control, vascular access, surgical procedures,
advanced wound care, and medical device coatings. To learn more
about Covalon, visit our website at www.covalon.com.
IV Clear®, MediClear®, and SurgiClear® are registered trademarks
of Covalon Technologies Ltd. in Canada, the United
States and the United
Kingdom.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Certain statements contained in this press release may
constitute forward-looking information. These statements relate to
future events or future performance. The use of any of the words
"could", "intend", "expect", "believe", "will", "projected",
"estimated", "proposed" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on the Company's
current believe or assumptions as to the outcome and timing of such
future events. Such forward-looking information is subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
statements. Various assumptions or factors are typically applied in
drawing conclusions or making the forecast or projections set out
in forward-looking information. Those assumptions and factors are
based on information currently available to the Company. The
forward-looking information contained in this press release is made
as of the date hereof and the Company is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue
reliance on forward-looking information. The foregoing statements
expressly qualify any forward-looking information contained
herein.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/covalon-granted-key-antimicrobial-patents-in-the-united-states-canada-and-europe-301069580.html
SOURCE Covalon Technologies Ltd.